Blue Horseshoe Stocks: Options Review, Other Updates

Options Review

Just to refresh our readers’ memories, we highlighted a range of call contracts for three separate plays on Friday, and we’re pleased to report that sizable gains were there for the taking regardless of which idea was chosen. It marked the continuation of a flawless streak of such ideas that we offered up over the past few weeks.

Our tracked calls and the magnitude of the gains that were available were as follows:

SPDR S&P 500 (SPY) Weekly $199-202 Calls – We’ve successfully played the SPY so many times it doesn’t even bear counting, and Friday was no different. From the low end of our range to the high, gains of 80-427% were made.

Finisar Corp FNSR Weekly $15 and $16 Calls – An earnings beat made the gains in FNSR calls possible, with the $15’s running 88%, and the $16’s making a 92% upswing.

Ulta Salon, Cosmetics & Fragrance, Inc. ULTA  Weekly $175-185 Calls –  Last but not least, we had the ULTA contracts on our watchlist bank gains running from 59-117%

Again, it was yet another great week for options, and we’ll be doing everything in our power to keep the streak alive with some more ideas this week so be sure to stay tuned!


Friday’s Stock Gainers

In addition to our great success with options plays from Friday’s morning report, we had a number of other intraday movers which were also highlighted.

Propanc Health Group Corp. PPCH

This was our top-billed mention on Friday, having been following it for most of last week. A string of solid performances led the stock on a great intraweek run to that point which spanned from our observed low of .0188 to .037 (+97%) in just a few sessions.

We saw even more gains tacked on there during Friday’s trading, wherein we witnessed another nice intraday pop from the daily low of .0355 to .0516 (+45%), and the high extended our total observed range to an impressive 174% in a matter of four sessions.

_____

Mexus Gold US (MXSG)

Mexus was another point of discussion in Friday’s newsletter, and it too saw appreciable gains on the day.

We’d already been very familiar with the stock after tracking over a more than 1000% move in early February. We then re-tagged it the Wednesday before last and subsequently witnessed a 61% swing from .011-.018.

Friday’s session brought a continuation of that run from .017 to a high of .0299, a 71% intraday rip, and increased the total swing range to 172%

_____

Spectrascience, Inc. SCIE

SCIE was included in Friday’s tracklist and the stock would end up trading in a range from .003 to .0047, for total possible intraday gains of up to 56% on slightly heavier than normal volume.

It also managed to close just a tick below the high of day, so we’ll keep an eye peeled for the possibility of momentum spillover into this new trading week.


GW Pharmaceuticals, Inc. GWPH

We want to pin GWPH to our tracklist after catching a significant PR coming across the wires this morning. Late-stage studies on a cannabidiol (CBD) treatment of a rare pediatric disease has yielded positive results, and the stock has thus far gapped up over 100% in the premarket.

We’ll take our classic stance of monitoring for a possible dip-and-rip situation and look to get positioned in some in-the-money Calls, dependent upon where the bounce occurs.

LONDON, March 14, 2016 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (GWPH) (GWP.L) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces the positive results of the first pivotal Phase 3 study of its investigational medicine Epidiolex® (cannabidiol or CBD) for the treatment of Dravet syndrome. (>> FULL PR)


Extended Watchlist:
DDD, TFM, GBIM, HPTG, USAR, IEEC, ASTI, SVTE